Skip to main content
. 2016 Sep;186(9):2429–2448. doi: 10.1016/j.ajpath.2016.05.021

Figure 2.

Figure 2

CT glycan staining in rAAVrh74.MCK.GALGT2-treated FKRP P448Lneo− muscle. A: The gastroc, quad, and TA muscles of FKRP P448Lneo− mice were injected with rAAVrh74.MCK.GALGT2 (treated) and analyzed at 1, 3, and 6 months after injection compared with contralateral PBS-injected controls (untreated). Cross-sections of muscle were stained with WFA (green) to label CT glycan overexpression and with an antibody to laminin α2 (red) to label the muscle sarcolemma. Nuclei were stained with DAPI (blue). B: Costaining with WFA lectin (green) and CT2 (red) to show WFA staining of CT glycan recognized by an anti-CT glycan antibody in rAAVrh74.MCK.GALGT2-treated muscle at 3 months after treatment. Overlap is shown in merged image in yellow. Scale bars: 100 μm (A); 50 μm (B). Ab, antibody; CT, cytotoxic T cell; GALGT2, β-1,4 N-acetylgalactosaminyltransferase 2; gastroc, gastrocnemius; MCK, muscle creatine kinase; PBS, phosphate-buffered saline; quad, quadriceps; rAAV, recombinant adeno-associated virus; TA, tibialis anterior; WFA, Wisteria floribunda agglutinin.